Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-05

FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for the irbesartan and hydrochlorothiazide product from Hikma Pharmaceuticals USA, updating labeling as part of the supp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IRBESARTAN AND HYDROCHLOROTHIAZIDE (irbesartan and hydrochlorothiazide)

Snippet

SUPPL AP for IRBESARTAN AND HYDROCHLOROTHIAZIDE (IRBESARTAN AND HYDROCHLOROTHIAZIDE)